At baseline, there were no significant differences between the tacrolimus and telitacicept groups in terms of gender, age, baseline MG clinical scores, or baseline BAFF levels (Figure 8C; Table S4, Supporting Information). The gene discussed is TNFSF13B; the disease is myasthenia gravis.